Limits...
An In silico Chimeric Vaccine Targeting Breast Cancer Containing Inherent Adjuvant.

Imani Fooladi AA, Mahmoodzadeh Hosseini H, Amani J - Iran J Cancer Prev (2015)

Bottom Line: We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct.Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.

View Article: PubMed Central - PubMed

Affiliation: Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

ABSTRACT

Background: Today, Lack of efficient therapeutic strategy for breast cancer (the most common cause of death in women) is one of the momentous problematic topics for all health care committees. Designing new specific vaccine, based on antigens located on the surface of cancer cells can be useful. Over expression of ROR1, lacked of HER2/neu, and hormone receptors on cell surface in the breast cancer, introduce this protein as an appropriate candidate for designing cancer vaccine.

Objectives: We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.

Materials and methods: Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct. In addition, the stability, physic-chemical properties and allergic potency of designed fusion protein were investigated by valid bioinformatics software.

Results: Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.

Conclusions: The ROR-1 with an enterotoxin B could be a potent vaccine for breast cancer.

No MeSH data available.


Related in: MedlinePlus

Graphical outcomes for predicting the secondary structure of ROR1-SEB. Blue, purple and red indicate the Helix, extended strand and random coiled structures, respectively
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581362&req=5

A2326FIG2: Graphical outcomes for predicting the secondary structure of ROR1-SEB. Blue, purple and red indicate the Helix, extended strand and random coiled structures, respectively

Mentions: Figure 2 illustrates the pattern of secondary structure of ROR1-SEB predicted by GOR IV. Based on our findings, the structural content of ROR1-SEB was composed of 18.64% alpha helix, 27.38% extended strands and 53.98% random coil. Full length of ROR1-SEB is made up of 33 random coils, 30 extended strands and 11 alpha helices. As summarized in Table 1, the secondary structure pattern of the chimeric protein is similar to the extracellular part of ROR1 and SEB.


An In silico Chimeric Vaccine Targeting Breast Cancer Containing Inherent Adjuvant.

Imani Fooladi AA, Mahmoodzadeh Hosseini H, Amani J - Iran J Cancer Prev (2015)

Graphical outcomes for predicting the secondary structure of ROR1-SEB. Blue, purple and red indicate the Helix, extended strand and random coiled structures, respectively
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581362&req=5

A2326FIG2: Graphical outcomes for predicting the secondary structure of ROR1-SEB. Blue, purple and red indicate the Helix, extended strand and random coiled structures, respectively
Mentions: Figure 2 illustrates the pattern of secondary structure of ROR1-SEB predicted by GOR IV. Based on our findings, the structural content of ROR1-SEB was composed of 18.64% alpha helix, 27.38% extended strands and 53.98% random coil. Full length of ROR1-SEB is made up of 33 random coils, 30 extended strands and 11 alpha helices. As summarized in Table 1, the secondary structure pattern of the chimeric protein is similar to the extracellular part of ROR1 and SEB.

Bottom Line: We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct.Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.

View Article: PubMed Central - PubMed

Affiliation: Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

ABSTRACT

Background: Today, Lack of efficient therapeutic strategy for breast cancer (the most common cause of death in women) is one of the momentous problematic topics for all health care committees. Designing new specific vaccine, based on antigens located on the surface of cancer cells can be useful. Over expression of ROR1, lacked of HER2/neu, and hormone receptors on cell surface in the breast cancer, introduce this protein as an appropriate candidate for designing cancer vaccine.

Objectives: We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.

Materials and methods: Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct. In addition, the stability, physic-chemical properties and allergic potency of designed fusion protein were investigated by valid bioinformatics software.

Results: Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.

Conclusions: The ROR-1 with an enterotoxin B could be a potent vaccine for breast cancer.

No MeSH data available.


Related in: MedlinePlus